It is defined as a novel synthetic compound that can be administered orally for the allosteric inhibition of Akt. This novel molecule requires the pleckstrin homology domain for its action and that’s why it acts as a selective inhibitor of Akt. Studies reported that it is equally potent to inhibit the AKt1 and Akt2 enzymes but is almost 5 times less potent to inhibit the Akt3 enzyme.

T-5224 is a small molecule that is non-peptidic in nature. It acts as an inhibitor of activator protein/c-Fos (transcription factors) by inhibiting the binding of activator protein AP-1 to the AP binding site, thus showing anti-inflammatory effects. It regulates the gene expressions for the pro-inflammatory cytokines.

Alzheimer's disease (AD) is a major neurodegenerative disease that seriously threatens human health. It is estimated that there will be more than 70 million AD patients worldwide in 2030, bringing a heavy burden to patients, families and society.